Skip to main content

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

Abstract

In postmenopausal women with hormone receptor-positive early-stage breast cancer, the use of aromatase inhibitors (AIs) to suppress estrogen is associated with improved clinical outcomes compared with tamoxifen therapy. Women receiving such endocrine therapy may experience treatment-related side effects that negatively affect health-related quality of life (QoL) and adherence to therapy. In published clinical trials and in clinical practice, adverse events (AEs) constitute the main reason for nonadherence to endocrine treatment. Serious AEs are sometimes resolved by switching to a different agent, whereas other side effects can often be managed to allow patients to remain on therapy without sacrificing QoL. Across all adjuvant endocrine trials, regardless of the treatment received, vasomotor symptoms such as hot flashes are the most common side effects. Other frequently reported side effects, such as vaginal discharge, vaginal dryness, dyspareunia, and arthralgia, vary in prevalence between tamoxifen and AIs. Here we provide an overview of reported AEs of adjuvant endocrine therapy, focusing on those that are amenable to pharmacologic or nonpharmacologic management without treatment discontinuation. Also highlighted are specific management strategies that may improve patient QoL and thereby optimize adherence to therapy, which in turn might improve patient outcomes.

This is a preview of subscription content, access via your institution.

References

  1. ATAC Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) randomised trial. Lancet 359:2131–2139

    Article  Google Scholar 

  2. Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62

    PubMed  Article  CAS  Google Scholar 

  3. Thürlimann B, Keshaviah A, Coates AS et al, for the Breast International Group (BIG) 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757

    Google Scholar 

  4. Coombes RC, Hall E, Gibson LJ et al, for the Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092

    Google Scholar 

  5. Jakesz R, Jonat W, Gnant M et al, on behalf of the ABCSG and the GABG (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462

    Google Scholar 

  6. Boccardo F, Rubagotti A, Puntoni M et al (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23:5138–5147

    PubMed  Article  CAS  Google Scholar 

  7. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271

    PubMed  CAS  Google Scholar 

  8. Jakesz R, Samonigg H, Greil R et al (2005) Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 23:526 (abstract)

    Google Scholar 

  9. Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629

    PubMed  Article  CAS  Google Scholar 

  10. National Comprehensive Cancer Network (2005) Breast cancer: clinical practice guidelines in oncology – v.2.2005. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Cited 14 June 2005

  11. Whelan TJ, Pritchard KI (2006) Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 12:1056s–1060s

    PubMed  Article  CAS  Google Scholar 

  12. Partridge AH (2006) Non-adherence to endocrine therapy for breast cancer. Ann Oncol 17:183–184

    PubMed  Article  CAS  Google Scholar 

  13. Partridge AH, Wang PS, Winer EP et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606

    PubMed  Article  CAS  Google Scholar 

  14. Fallowfield L, Atkins L, Catt S et al (2006) Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17:205–210

    PubMed  Article  CAS  Google Scholar 

  15. Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42:2271–2276

    PubMed  Article  Google Scholar 

  16. Lash TL, Fox MP, Westrup JL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215–220

    PubMed  Article  Google Scholar 

  17. Grunfeld EA, Hunter MS, Sikka P et al (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97–102

    PubMed  Article  Google Scholar 

  18. Wasan KM, Goss PE, Pritchard PH et al (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16:707–715

    PubMed  Article  CAS  Google Scholar 

  19. Sloan JA, Frost MH, Berzon R et al (2006) The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer 14:988–998

    PubMed  Article  Google Scholar 

  20. Fallowfield L, Cella D, Cuzick J et al (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22:4261–4271

    PubMed  Article  CAS  Google Scholar 

  21. Cella D, Fallowfield L, on behalf of the ATAC Trialists’ Group (2005) Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the arimidex (A), tamoxifen (T), alone or in combination (ATAC) trial. J Clin Oncol 23:577 (abstract)

    Google Scholar 

  22. Cella D, Fallowfield L, Barker P et al (2006) Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100:273–284

    PubMed  Article  Google Scholar 

  23. Massacesi C, Zepponi L, Rocchi MB et al (2006) Tamoxifen-related endocrine symptoms in early breast cancer patients are relieved when it is switched to anastrozole. J Clin Oncol 24:10597 (abstract)

    Google Scholar 

  24. Fallowfield LJ, Bliss JM, Porter LS et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910–917

    PubMed  Article  CAS  Google Scholar 

  25. Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931–6940

    PubMed  Article  CAS  Google Scholar 

  26. Fellowes D, Fallowfield LJ, Saunders CM et al (2001) Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments?. Breast Cancer Res Treat 66:73–81

    PubMed  Article  CAS  Google Scholar 

  27. Coombes C, Bliss J, Hall E et al (2003) Under-reporting of symptoms in patients with early breast cancer (EBC) who have received tamoxifen treatment for 2–3 years. Proc Am Soc Clin Oncol 22:13 (abstract 48)

    Google Scholar 

  28. Fallowfield L, Cella D, on behalf of the ATAC Trialists’ Group (2002) Assessing the quality of life (QOL) of postmenopausal women randomized into the ATAC (‘arimidex’, tamoxifen, alone or in combination) adjuvant breast cancer trial. Poster presented at: American Society of Clinical Oncology 38th Annual Meeting; May 18–21, 2002; Orlando, FL

  29. Buzdar A, Howell A, Cuzick J et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633–643

    PubMed  Article  CAS  Google Scholar 

  30. Morales L, Neven P, Paridaens R (2005) Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 17:559–565

    PubMed  Article  CAS  Google Scholar 

  31. Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78–84

    PubMed  CAS  Google Scholar 

  32. Viale PH (2005) Aromatase inhibitor agents in breast cancer: evolving practices in hormonal therapy treatment. Oncol Nurs Forum 32:343–353

    PubMed  Article  Google Scholar 

  33. Taylor M, Rastelli A, Civitelli R et al (2004) Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. Abstract presented at the 27th Annual San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, TX

  34. Thompson JN, Napoli N, Civitelli R et al (2006) Effects of dietary calcium vs. calcium supplements on estrogen metabolism and bone density. Osteoporos Int 17:S205 (abstract P696MO)

    Google Scholar 

  35. Rosen LS, Gordon DH, Dugan W Jr et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36–43

    PubMed  Article  CAS  Google Scholar 

  36. Brufsky A (2006) Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 33:S13–S17

    PubMed  Article  CAS  Google Scholar 

  37. Anastrozole bisphosphonate study in postmenopausal women with hormone-receptor-positive early breast cancer. Available at: http://www.clinicaltrials.gov/ct/show/NCT00082277. Cited 10 October 2006

  38. McClung MR (2006) Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 4:28–33

    PubMed  Article  Google Scholar 

  39. Hamdy NAT (2005) Osteoprotegerin as a potential therapy for osteoporosis. Curr Osteoporos Rep 3:121–125

    PubMed  Article  Google Scholar 

  40. Harrington L, Schneider JI (2006) Atraumatic joint and limb pain in the elderly. Emerg Med Clin N Am 24:389–412

    Article  Google Scholar 

  41. Sarzi-Puttini P, Atzeni F, Capsoni F et al (2005) Drug-induced lupus erythematosus. Autoimmunity 38:507–518

    PubMed  Article  CAS  Google Scholar 

  42. Abu-Khalaf MM, Windsor S, Ebisu K et al (2005) Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology 69:372–383

    PubMed  Article  CAS  Google Scholar 

  43. Formenti SC, Volm M, Skinner KA et al (2003) Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol 21:864–870

    PubMed  Article  CAS  Google Scholar 

  44. Donnellan PP, Douglas SL, Cameron DA et al (2001) Aromatase inhibitors and arthralgia. J Clin Oncol 19:2767

    PubMed  CAS  Google Scholar 

  45. McCloskey E (2006) Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 42:1044–1051

    PubMed  Article  CAS  Google Scholar 

  46. Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52:2594–2598

    PubMed  Article  CAS  Google Scholar 

  47. Plourde P, Locker G, Hoctin-Boes G et al (2005) Arthralgia in postmenopausal breast cancer patients on adjuvant endocrine therapy: a risk-benefit analysis. Poster presented at: 7th Annual Lynn Sage Breast Cancer Symposium; October 6–9 2005; Chicago, Illinois

  48. Mom CH, Buijs C, Willemse PHB et al (2006) Hot flushes in breast cancer patients. Crit Rev Oncol Hematol 57:63–77

    PubMed  Google Scholar 

  49. Holmberg L, Anderson H, for the HABITS Steering, Data Monitoring Committees (2004) HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet 363:453–455

    Google Scholar 

  50. Bertelli G, Venturini M, Del Mastro L et al (2002) Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 13:883–888

    PubMed  Article  CAS  Google Scholar 

  51. Barton DL, Loprinzi C, Atherton PJ et al (2006) Dehydroepiandrosterone for the treatment of hot flashes: a pilot study. Support Canc Ther 3:91–97

    CAS  Google Scholar 

  52. Loprinzi CL, Sloan JA, Perez EA et al (2002) Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20:1578–1583

    PubMed  Article  CAS  Google Scholar 

  53. Stearns V, Isaacs C, Rowland J et al (2000) A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 11:17–22

    PubMed  Article  CAS  Google Scholar 

  54. Stearns V, Beebe KL, Iyengar M et al (2003) Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289:2827–2834

    PubMed  Article  CAS  Google Scholar 

  55. Loprinzi CL, Kugler JW, Sloan JA et al (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356:2059–2063

    PubMed  Article  CAS  Google Scholar 

  56. Barton DL, Loprinzi CL, Novotny P et al (2003) Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 1:47–51

    PubMed  CAS  Google Scholar 

  57. Loprinzi CL, Levitt R, Barton D et al (2006) Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 24:1409–1414

    PubMed  Article  CAS  Google Scholar 

  58. Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39

    PubMed  CAS  Article  Google Scholar 

  59. Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764

    PubMed  CAS  Google Scholar 

  60. Pandya KJ, Morrow GR, Roscoe JA et al (2005) Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 366:818–824

    PubMed  Article  CAS  Google Scholar 

  61. Filshie J, Bolton T, Browne D et al (2005) Acupuncture and self acupuncture for long term treatment of vasomotor symptoms in cancer patients—audit and treatment algorithm. Acupunct Med 23:171–180

    PubMed  Article  Google Scholar 

  62. Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802

    PubMed  Article  CAS  Google Scholar 

  63. Schover LR (2005) Sexuality and fertility after cancer. Hematology (Am Soc Hematol Educ Program) 1:523–527

    Google Scholar 

  64. Kendall A, Dowsett M, Folkerd E et al (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584–587

    PubMed  Article  CAS  Google Scholar 

  65. Mok K, Mireskandari S, Juraskova I et al (2006) OVER (Olive oil Vaginal Exercises and Replens) Come. Psycho-Oncology 15:S332 (abstract 778)

    Google Scholar 

  66. Shifren JL, Braunstein GD, Simon JA et al (2000) Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343:682–688

    PubMed  Article  CAS  Google Scholar 

  67. Goldstat R, Briganti E, Tran J et al (2003) Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 10:390–398

    PubMed  Article  Google Scholar 

  68. Mathias C, Cardeal MC, Ponde de SE et al (2006) An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer. Ann Oncol 17:1792–1796

    PubMed  Article  CAS  Google Scholar 

  69. Gregorian RS, Golden KA, Bahce A et al (2002) Antidepressant-induced sexual dysfunction. Ann Pharmacother 36:1577–1589

    PubMed  Article  CAS  Google Scholar 

  70. Jansen CE, Miaskowski C, Dodd M et al (2005) Chemotherapy-induced cognitive impairment in women with breast cancer: a critique of the literature. Oncol Nurs Forum 32:329–342

    PubMed  Article  Google Scholar 

  71. Jenkins V, Shilling V, Deutsch G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834

    PubMed  Article  CAS  Google Scholar 

  72. van Dam FS, Schagen SB, Muller MJ et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218

    PubMed  Article  Google Scholar 

  73. Castellon SA, Ganz PA, Bower JE et al (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955–969

    PubMed  Article  Google Scholar 

  74. Ahles TA, Saykin AJ (2002) Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 3(Suppl 3):S84–S90

    PubMed  CAS  Google Scholar 

  75. Jenkins V, Shilling V, Fallowfield L et al (2004) Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology 13:61–66

    PubMed  Article  Google Scholar 

  76. Eberling JL, Wu C, Tong-Turnbeaugh R et al (2004) Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage 21:364–371

    PubMed  Article  Google Scholar 

  77. Ernst T, Chang L, Cooray D et al (2002) The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 94:592–597

    PubMed  CAS  Google Scholar 

  78. Ganz PA, Castellon SA, Silverman DH (2002) Estrogen, tamoxifen, and the brain. J Natl Cancer Inst 94:547–549

    PubMed  Google Scholar 

  79. Cimprich B, So H, Ronis DL et al (2005) Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology 14:70–78

    PubMed  Article  Google Scholar 

  80. Howell A, Cuzick J (2005) Vascular effects of aromatase inhibitors: data from clinical trials. J Steroid Biochem Mol Biol 95:143–149

    PubMed  Article  CAS  Google Scholar 

  81. Cella D (2006) Quality of life and clinical decisions in chemotherapy-induced anemia. Oncology (Williston Park) 20:25–28

    Google Scholar 

  82. Leyland-Jones B, O’Shaughnessy JA (2003) Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications. Semin Oncol 30:174–184

    PubMed  Article  CAS  Google Scholar 

  83. O’Shaughnessy JA, Vukelja SJ, Holmes FA et al (2005) Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 5:439–446

    PubMed  CAS  Google Scholar 

  84. Finelli PF, Carley MD (2000) Cerebral venous thrombosis associated with epoetin alfa therapy. Arch Neurol 57:260–262

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David Cella.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cella, D., Fallowfield, L.J. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107, 167–180 (2008). https://doi.org/10.1007/s10549-007-9548-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9548-1

Keywords

  • Breast cancer
  • Endocrine therapy
  • Adverse events
  • Aromatase
  • Tamoxifen
  • Quality of life
  • Adherence